Compare Citius Pharmaceuticals Inc (CTXR) vs ABRDN Physical Gold Shares ETF (SGOL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs ABRDN Physical Gold Shares ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while ABRDN Physical Gold Shares ETF trades at $38.71. The key difference: ABRDN Physical Gold Shares ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | SGOL | |
|---|---|---|
Market Cap | $14.64M | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $1.82 | $51.41 |
52-Week Low | $0.53 | $31.18 |
Enterprise Value | $10.86M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
SGOL is trading at $38.1, down 2.61% amid broader gold market weakness. The technical picture shows bearish momentum with moving averages signaling sell pressure, while oscillators remain neutral. Gold ETFs face headwinds from rising Treasury yields and Federal Reserve policy uncertainty, though central bank buying provides underlying support. Recent CPI data provided temporary relief but failed to sustain momentum.
The outlook remains cautious as gold faces competing forces - supportive central bank demand versus restrictive monetary policy. Near-term direction hinges on Fed policy clarity and inflation trends, with technical resistance at $39-$40 levels posing immediate challenges for bullish momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About ABRDN Physical Gold Shares ETF
SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →
